Eli Lilly makes $7.8bn takeover play for Centessa Sleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech.

#CentessaPharma is heading for an #acquisition by #EliLilly, which has offered $6.3 billion for the company, with another $1.5 billion in future payments tied to #FDA approvals of its lead drug for #sleepdisorders.